(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 3.7MM | +14% |
Gross Profit | 1.8MM | -1% |
Cost Of Revenue | 1.9MM | +34% |
Operating Income | -3.4MM | - |
Operating Expenses | 5.2MM | +76% |
Net Income | -4.1MM | - |
R&D | 4K | -64% |
G&A | 1.2MM | -3% |
Marketing | 1.4MM | -18% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
EMERYVILLE, Calif., April 22, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products. The new and enhanced programs build upon the Company’s past highly productive marketing pr
EMERYVILLE, Calif., April 19, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with the
EMERYVILLE, Calif., April 17, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript March 26, 2024 NovaBay Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.95 EPS, expectations were $-0.3. NBY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to […]
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
EMERYVILLE, Calif., March 26, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
EMERYVILLE, Calif., March 25, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
EMERYVILLE, Calif., March 14, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAdoctor® skincare business including all product inventory for approximately $1.0 million in cash. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days.
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery,
EMERYVILLE, Calif., January 30, 2024--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com. A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022. In addition, of the more than 13,000 customer reviews across all online channels, Avenova